Page 114 - 《中国药房》2023年22期

et al. Ribociclib as first-line therapy for HR-positive， [25] TURNER N C，RO J，ANDRÉ F，et al. Palbociclib in
advanced breast cancer[J]. N Engl J Med，2016，375（18）： hormone-receptor-positive advanced breast cancer[J]. N
1738-1748. Engl J Med，2015，373（3）：209-219.
[16] HORTOBAGYI G N，STEMMER S M，BURRIS H A， [26] CRISTOFANILLI M，RUGO H S，IM S A，et al. Overall
et al. Overall survival with ribociclib plus letrozole in survival with palbociclib and fulvestrant in women with
advanced breast cancer[J]. N Engl J Med，2022，386（10）： HR /HER2 ABC：updated exploratory analysis of PALOMA-
－
+
942-950. 3，a double-blind，phase Ⅲ randomized study[J]. Clin
[17] SLAMON D J，NEVEN P，CHIA S，et al. Phase Ⅲ ran‐ Cancer Res，2022，28（16）：3433-3442.
domized study of ribociclib and fulvestrant in hormone [27] XU B H，HU X C，LI W，et al. Palbociclib plus letrozole
receptor-positive，human epidermal growth factor receptor versus placebo plus letrozole in Asian postmenopausal
2-negative advanced breast cancer：MONALEESA-3[J]. J women with oestrogen receptor-positive/human epidermal
Clin Oncol，2018，36（24）：2465-2472. growth factor receptor 2-negative advanced breast cancer：
[18] SLAMON D J，NEVEN P，CHIA S，et al. Ribociclib plus primary results from PALOMA-4[J]. Eur J Cancer，2022，
fulvestrant for postmenopausal women with hormone 175：236-245.
receptor-positive，human epidermal growth factor receptor [28] LOIBL S，MARMÉ F，MARTIN M，et al. Palbociclib for
2-negative advanced breast cancer in the phase Ⅲ rando- residual high-risk invasive HR-positive and HER2-nega‐
mized MONALEESA-3 trial：updated overall survival[J]. tive early breast cancer-the penelope-B trial[J]. J Clin On‐
Ann Oncol，2021，32（8）：1015-1024. col，2021，39（14）：1518-1530.
[19] TRIPATHY D，IM S A，COLLEONI M，et al. Ribociclib [29] GNANT M，DUECK A C，FRANTAL S，et al. Adjuvant
plus endocrine therapy for premenopausal women palbociclib for early breast cancer：the PALLAS trial
with hormone-receptor-positive，advanced breast cancer results（ABCSG-42/AFT-05/BIG-14-03）[J]. J Clin Oncol，
（MONALEESA-7）：a randomised phase 3 trial[J]. Lancet 2022，40（3）：282-293.
Oncol，2018，19（7）：904-915. [30] ALBANELL J，MARTÍNEZ M T，RAMOS M，et al. Ran‐
[20] LU Y S，IM S A，COLLEONI M，et al. Updated overall domized phase Ⅱ study of fulvestrant plus palbociclib or
survival of ribociclib plus endocrine therapy versus endo‐ placebo in endocrine-sensitive，hormone receptor-positive/
crine therapy alone in pre- and perimenopausal patients HER2-advanced breast cancer：GEICAM/2014-12（FLIPPER）
with HR /HER2 advanced breast cancer in MONALEESA- [J]. Eur J Cancer，2022，161：26-37.
－
+
7：a phase Ⅲ randomized clinical trial[J]. Clin Cancer [31] DUKELOW T，KISHAN D，KHASRAW M，et al. CDK4/
Res，2022，28（5）：851-859. 6 inhibitors in breast cancer[J]. Anti Cancer Drugs，2015，
[21] FINN R S，CROWN J P，LANG I，et al. The cyclin- 26（8）：797-806.
dependent kinase 4/6 inhibitor palbociclib in combination [32] FINN R S，DERING J，CONKLIN D，et al. PD 0332991，
with letrozole versus letrozole alone as first-line treatment a selective cyclin D kinase 4/6 inhibitor，preferentially
of oestrogen receptor-positive，HER2-negative，advanced inhibits proliferation of luminal estrogen receptor-positive
breast cancer （PALOMA-1/TRIO-18） ：a randomised human breast cancer cell lines in vitro[J]. Breast Cancer
phase 2 study[J]. Lancet Oncol，2015，16（1）：25-35. Res，2009，11（5）：R77.
[22] FINN R S，BOER K，BONDARENKO I，et al. Overall [33] ONESTI C E，JERUSALEM G. CDK4/6 inhibitors in
survival results from the randomized phase 2 study of pal‐ breast cancer：differences in toxicity profiles and impact
bociclib in combination with letrozole versus letrozole on agent choice： a systematic review and meta-analysis
alone for first-line treatment of ER /HER2 advanced [J]. Expert Rev Anticancer Ther，2021，21（3）：283-298.
－
+
breast cancer（PALOMA-1，TRIO-18）[J]. Breast Cancer [34] LAURENTI E，FRELIN C，XIE S，et al. CDK6 levels
Res Treat，2020，183（2）：419-428. regulate quiescence exit in human hematopoietic stem
[23] FINN R S，MARTIN M，RUGO H S，et al. Palbociclib cells[J]. Cell Stem Cell，2015，16（3）：302-313.
and letrozole in advanced breast cancer[J]. N Engl J Med， [35] SPRING L M，WANDER S A，ANDRE F，et al. Cyclin-
2016，375（20）：1925-1936. dependent kinase 4 and 6 inhibitors for hormone receptor-
[24] RUGO H S，FINN R S，DIÉRAS V，et al. Palbociclib plus positive breast cancer：past，present，and future[J]. Lancet，
letrozole as first-line therapy in estrogen receptor-positive/ 2020，395（10226）：817-827.
human epidermal growth factor receptor 2-negative advanced （收稿日期：2023-05-05 修回日期：2023-10-25）
breast cancer with extended follow-up[J]. Breast Cancer （编辑：陈 宏）
Res Treat，2019，174（3）：719-729.

· 2792 · China Pharmacy 2023 Vol. 34 No. 22 中国药房 2023年第34卷第22期